Table 6.
Common lower-bound assay μ(ComboTNN-NI) outliers.
| μ(ComboT NN-NI ) | |||||
|---|---|---|---|---|---|
| AID | Type a | Description | |||
| ST-opt | CT-opt | Ave. b | |||
| 1349 | (P) | -0.27 | -0.22 | -0.24 | Test of compound activity against tunicamycin-induced cell death using Flow cytometry in CSM14.1 undifferentiated cells. |
| 1343 | (P) | -0.18 | -0.20 | -0.19 | Test of compound activity against tunicamycin-induced cell death using an ATP content assay in CSM14.1 undifferentiated cells. |
| 1218 | (P) | -0.11 | -0.16 | -0.13 | Functional assay for estrogen-mediated translocation of PIP3: Secondary Assay for Estrogen receptor beta. |
| 1219 | (P) | -0.11 | -0.16 | -0.13 | Functional assay to assess estrogen-mediated translocation of PIP3: Secondary Assay for GPR30 estrogen receptor. |
| 1711 | (C) | -0.12 | -0.13 | -0.13 | Concentration-Response Counterscreen for Tau: Redox Active Inhibitors of Caspase-1 |
| 1247 | (C) | -0.14 | -0.10 | -0.12 | Dose Response Assay for SAR studies of Inhibitors of ER stress-Induced Cell Death: A Benzodiazepine Series |
| 839 | (C) | -0.09 | -0.12 | -0.10 | Screening for Modulators of Post-Golgi Transport - Secondary Growth Assay. |
| 495 | (O) | -0.07 | -0.14 | -0.10 | Literature data for small-molecule inhibitors of Influenza A Subtype N2. |
| 931 | (C) | -0.10 | -0.11 | -0.10 | Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus: Cytotoxicity |
| 791 | (C) | -0.10 | -0.08 | -0.09 | Dose-response biochemical assay of Rho kinase 2 (Rock2) inhibitors |
| 769 | (C) | -0.09 | -0.07 | -0.08 | Dose response biochemical assay for autofluorescent inhibitors of Matrix Metalloproteinase 13 (MMP13) activity |
| 302 | (?) | -0.06 | -0.08 | -0.07 | NCI In Vivo Anticancer Drug Screen. Data for tumor model Madison 109 Lung Carcinoma (intramuscular) in BALB/CM mice |
| 1225 | (C) | -0.05 | -0.07 | -0.06 | Dose Response cell-based high-throughput screening assay to identify antagonists of galanin receptor 2 (GALR2) |
| 1226 | (P) | -0.05 | -0.07 | -0.06 | Functional assay for estrogen-mediated translocation of PIP3: Secondary Assay for Estrogen receptor alpha |
| 2110 | (C) | -0.05 | -0.07 | -0.06 | Confirmation of Inhibitors and Activators of Purified Human alpha-Glucosidase Using an Alternate Red Fluorescent Susbtrate |
| 1331 | (C) | -0.04 | -0.08 | -0.06 | Dose response biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) |
| 324 | (?) | -0.06 | -0.05 | -0.06 | NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice |
| 1342 | (C) | -0.05 | -0.06 | -0.06 | Fluorescence polarization assay for PKD inhibitiors-interference assay-57K HTS campaign |
| 308 | (?) | -0.05 | -0.05 | -0.05 | NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia resistant to 6-MP and 6-Thioguanine; NSC 755, NSC 752 (intraperitoneal) in B6D2F1 (BDF1) mice |
| 1659 | (C) | -0.04 | -0.06 | -0.05 | SAR assay for compounds activating TNAP in the presence of 100 mM DEA performed in a luminescence assay |
| 658 | (C) | -0.04 | -0.06 | -0.05 | Cellular Toxicity (caspase-3) BJ |
| 632 | (C) | -0.04 | -0.06 | -0.05 | Confirmation Concentration-Response Assay and Counterscreen for Disrupters of an Hsp90 Co-Chaperone Interaction |
| 238 | (?) | -0.05 | -0.04 | -0.04 | NCI In Vivo Anticancer Drug Screen. Data for tumor model Leiomyosarcoma (No. 2) (intraperitoneal) in CAF1 mice |
| 856 | (C) | -0.04 | -0.05 | -0.04 | Counterscreen for S1P2 Antagonists: Dose Response Cell-Based Screen to Identify Antagonists of CRE-BLA |
| 232 | (?) | -0.04 | -0.05 | -0.04 | NCI In Vivo Anticancer Drug Screen. Data for tumor model Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3AKF1 (CHKRF1) mice |
| 369 | (O) | -0.04 | -0.04 | -0.04 | Literature data for small-molecule inhibitors of Avian Sarcoma Virus Src. |
A list of AIDs whose difference in the average ComboT similarity scores between noninactive-noninactive (NN) pairs and noninactive-inactive (NI) pairs is greater in magnitude than μ[μ(ComboTNN-NI)] - σ[μ(ComboTNN-NI)] for both superposition optimization types.
a (P), (primary) screening; (C), confirmatory; (S), summary; (O), others; (?), unspecified.
b The average of ST-optimized and CT-optimized ComboTNN-NI.